Managing Luspatercept Super Responders (Dose Reduce vs Hold Dose)
FACE-OFF: Low-Risk MDS SOHO 2025
Panelists discuss how to optimize treatment approaches for patients with lower-risk myelodysplastic syndrome through a competitive debate format covering luspatercept vs erythropoiesis-stimulating agents as first-line therapy, management of super-responders, timing of treatment initiation, and real-world evidence from recent clinical trials including COMMANDS, MEDALIST, and IMerge.
| WATCH NOW |
Featured Video
| Debate Round 2: Managing Luspatercept Super Responders (Dose Reduce vs Hold Dose) Panelists discuss how to manage luspatercept “super responders” with hemoglobin levels above 12 g/dL, with Team Whataburger advocating for dose reduction to maintain stable responses and avoid hemoglobin fluctuations that disrupt patients’ quality of life, while Team In-and-Out argues for holding doses due to lack of safety data at very high hemoglobin levels and cost considerations. However, both teams acknowledge the need for individualized approaches and question whether current hemoglobin ceiling limits are appropriate for patients with MDS.
|